Page last updated: 2024-12-09

thiobenzamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thiobenzamide: structure; hepatotoxin in rats [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID683563
CHEMBL ID3739883
CHEBI ID80418
SCHEMBL ID67048
MeSH IDM0064886

Synonyms (39)

Synonym
UPCMLD00WV-103:002
benzamide, thio-
tiobenzamide [italian]
benzothiamide
einecs 218-765-6
benzothioamide
UPCMLD00WV-103
thiobenzamide
2227-79-4
benzenecarbothioamide
AO-840/40187641
inchi=1/c7h7ns/c8-7(9)6-4-2-1-3-5-6/h1-5h,(h2,8,9
thiobenzamide, 98%
T0194
AKOS000119942
unii-8799vm9sxc
8799vm9sxc ,
tiobenzamide
A816082
benzothioamide;benzenecarbothioamide
FT-0634151
SCHEMBL67048
CHEBI:80418
thio-benzamide
DTXSID8062280
phenylthioamide
F3143-0096
CHEMBL3739883 ,
mfcd00008060
J-014622
Z57070430
benzene-1-carbothioamide
Q27149460
AS-15711
AMY13371
EN300-17896
STL183325
bdbm50499815
CS-W016517

Research Excerpts

Overview

Thiobenzamide (TB) is a thiono-containing compound endowed with liver-damaging properties and promoting ability on liver carcinogenesis. TB causes dose-dependent hyperbilirubinemia, steatosis, and centrolobular necrosis.

ExcerptReferenceRelevance
"Thiobenzamide (TB) is a potent hepatotoxin in rats, causing dose-dependent hyperbilirubinemia, steatosis, and centrolobular necrosis. "( Protein targets of reactive metabolites of thiobenzamide in rat liver in vivo.
Duzhak, TG; Galeva, NA; Hanzlik, RP; Ikehata, K; Ji, T; Koen, YM, 2008
)
2.05
"Thiobenzamide (TB) is a thiono-containing compound endowed with liver-damaging properties and promoting ability on liver carcinogenesis. "( Effects of thiobenzamide on the rat immune system.
Ettorre, V; Malvaldi, G; Pasquinelli, P; Pieracci, D; Puccini, M; Vaglini, F, 1989
)
2.11

Toxicity

ExcerptReferenceRelevance
" In accordance with previous studies with the rat, p-methoxythiobenzamide was more toxic than thiobenzamide, and conversely p-chlorothiobenzamide was markedly less toxic as assessed by serum alanine aminotransferase (ALT) activity."( Relative hepatotoxicity of 2-(substituted phenyl)thiazoles and substituted thiobenzamides in mice: evidence for the involvement of thiobenzamides as ring cleavage metabolites in the hepatotoxicity of 2-phenylthiazoles.
Mizutani, T; Suzuki, K, 1996
)
0.77

Dosage Studied

ExcerptRelevanceReference
" Intraperitoneal dosing with thiobenzamide gave less severe necrosis and more pronounced elevations in bile acids, while oral dosing led to more severe necrosis along with impaired biliary function."( Thiobenzamide-induced hepatotoxicity: effects of substituents and route of administration on the nature and extent of liver injury.
DeLuca, JG; Grossman, SJ; Herold, EG; Kornbrust, D; Patrick, DH; Smith, PF; Zacchei, AG, 1991
)
2.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)2.80000.03403.987110.0000AID1265266
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusKic0.70000.70002.30004.3000AID1265268
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1265269Binding affinity to mushroom tyrosinase assessed as fluorescence quenching2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265270Cytotoxicity against mouse B16F10 cells assessed as cell survival at 50 uM after 48 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265271Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 10 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265274Inhibition of tyrosinase in mouse B16F10 cell lysates using DOPA as substrate relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265266Inhibition of mushroom tyrosinase using L-tyrosine as substrate2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1377269Drug degradation in phosphate buffer assessed as H2S release by measuring test compound half life at 40 uM measured every 5 mins in presence of TECP by UV-Vis spectrometry2017European journal of medicinal chemistry, Sep-29, Volume: 138Syntheses, toxicities and anti-inflammation of H
AID1265268Non-competitive inhibition of mushroom tyrosinase using L-tyrosine as substrate by Lineweaver-Burk plots analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265273Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 50 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1377270Drug degradation in phosphate buffer assessed as H2S release by measuring H2S Cmax at 40 uM measured every 5 mins in presence of TCEP by UV-Vis spectrometry2017European journal of medicinal chemistry, Sep-29, Volume: 138Syntheses, toxicities and anti-inflammation of H
AID1265272Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 20 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-199043 (58.11)18.7374
1990's15 (20.27)18.2507
2000's8 (10.81)29.6817
2010's7 (9.46)24.3611
2020's1 (1.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.03 (24.57)
Research Supply Index4.38 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index35.06 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other79 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]